KONEXElectrical Equipment402420

Calth

₩1,230 0.00%2026-11-18 close
Market Cap
₩2.9B
Turnover
₩0
Volume
0 shares
Shares out.
2.4M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

A small diagnostics name pivoting under capital strain

Sales keep shrinking and equity has only just turned positive, while Calth pursues saliva diagnostics and a SaaS subscription model.

  1. 1

    Revenue fell from KRW 12.5 billion in 2022 to KRW 1.686 billion in 2025, a third straight annual decline.

  2. 2

    Total equity at end-2025 was KRW 260 million, turning positive from a deficit at end-2024 but still below the KRW 2.13 billion capital stock.

  3. 3

    At a June 18, 2026 investor briefing, the company outlined a plan to move from kit-supply B2B to a SaaS subscription model.

  4. 4

    Saliva diagnostics built on ion concentration polarization and an AI analysis platform are in development, with commercialization timing not yet confirmed in filings.

  5. 5

    Trading value of KRW 1.014 million and a market capitalization of KRW 3.1 billion indicate very limited liquidity.

02

Business structure

Calth was founded in March 2018 as an in-vitro diagnostics device maker and listed on the Konex market in November 2021. Although the sector is classified as electrical equipment, the business is point-of-care diagnostic devices and consumable kits.

Its core technology is ion concentration polarization, which applies an electric field to ions so that they migrate selectively and concentrate. The company combines this with biosample pretreatment and concentration technology and a deep-learning analysis platform to develop saliva-based diagnostics.

Its product line started with COVID-19 test kits, and it expanded sales after securing approvals and certifications.

Revenue has relied on kit supply on a B2B basis, but at a June 18, 2026 briefing the company presented a plan to shift to a SaaS subscription model (B2C and DTC) built on smartphone AI analysis infrastructure.

Declining demand and intensifying competition in the in-vitro diagnostics market were cited as reasons for the 2024 revenue decline.

Unlike HD Hyundai Electric or LS ELECTRIC, which share the electrical equipment classification, Calth's business base differs from power equipment manufacturing and it competes with domestic diagnostics makers. Revenue breakdown by segment and product should be confirmed in the original DART filings. Headquarters and the factory are in Gunpo, Gyeonggi Province, and the CEO is Lee Dong-ho.

03

Recent trends

Standalone revenue in 2025 was KRW 1.686 billion, down from KRW 1.943 billion in 2024. The operating loss for 2025 was KRW 4.0 billion and the net loss was KRW 4.533 billion. In 2024 the operating loss was KRW 4.8 billion and the net loss was KRW 5.07 billion, so losses narrowed somewhat in 2025.

Revenue fell 13.24 percent in 2025, continuing a slide from KRW 12.5 billion in 2022 to KRW 2.99 billion in 2023 and KRW 1.94 billion in 2024. Total assets at end-2025 were KRW 6.78 billion, liabilities KRW 6.518 billion, and equity KRW 260 million.

Equity stood at a deficit of KRW 16.78 billion at end-2024 before turning positive at end-2025, and the capital changes behind that shift should be confirmed in the original filings. Operating cash flow in 2025 was negative KRW 2.15 billion.

At the March 26, 2026 shareholders' meeting, the eighth-term financial statements and the appointment of Lee Young-ju as an inside director were approved. According to a Hankyung data snapshot dated September 3, 2025, the share price was KRW 1,700 and the 12-month change was -86.65 percent.

As of 02:10 KST on November 11, 2026, the share price was KRW 1,300, down 5.45 percent from the prior close, with a market capitalization of KRW 3.1 billion.

04

Outlook

Three points are worth tracking. First, the reason equity turned positive at end-2025 and the details of capital stock changes need to be confirmed in the original filings.

Second, the timing and scale at which the SaaS subscription model appears in revenue will be visible in filings that separate kit sales from subscription sales. Third, the commercialization timing and regulatory progress of saliva-based diagnostics will be defined by future disclosures.

Revenue has declined since 2022, so product shipments or new channel expansion that support a recovery are the key indicators. The operating loss narrowed to about KRW 4.0 billion in 2025, but the scale of structural improvement depends on revenue recovery.

Operating cash flow remained negative, so external funding and its terms will affect the financial trajectory. Trading value of KRW 1.014 million points to limited liquidity on the Konex market, and price swings can be large.

05

Bull factors

Equity back above zero

Equity moved from a deficit of KRW 16.78 billion at end-2024 to KRW 260 million at end-2025, ending the capital impairment. The change matters for financial stability. Equity still sits below the KRW 2.13 billion capital stock, so the recovery is limited. The capital changes behind the shift should be confirmed in the original filings.

ICP-based saliva diagnostics

Ion concentration polarization (ICP) selectively moves charged ions with an electric field to concentrate them. Building on this, the company is developing products that aim to diagnose conditions and infectious diseases from saliva rather than blood.

Combining biosample pretreatment with a deep-learning analysis platform is presented as a differentiator. Commercialization timing and performance validation remain to be confirmed.

Planned shift to SaaS subscriptions

At a June 18, 2026 investor briefing, the company presented a plan to move from consumable kit sales in B2B to a SaaS subscription model in B2C and DTC. According to the company, a smartphone-based AI analysis infrastructure could reduce reliance on consumable sales.

The revenue impact of the plan has not yet appeared in filings. Whether subscription revenue grows as a share of sales is a matter for future disclosures.

06

Bear factors

Three straight years of revenue decline

Revenue fell from KRW 12.5 billion in 2022 to KRW 2.99 billion in 2023, KRW 1.94 billion in 2024, and KRW 1.686 billion in 2025. Lower demand and heavier competition in the in-vitro diagnostics market were cited as the causes. The 2025 revenue change of -13.24 percent shows the decline has not eased. Evidence of product or channel expansion that could support a recovery has not yet appeared in filings.

Persistent losses and thin equity

The 2025 operating loss was KRW 4.0 billion and the net loss was KRW 4.533 billion. Liabilities of KRW 6.518 billion at end-2025 are close to total assets of KRW 6.78 billion. Equity of KRW 260 million leaves little cushion. Operating cash flow remained negative at KRW 2.15 billion.

Steep share price decline and thin trading

According to a Hankyung snapshot dated September 3, 2025, the 12-month share price change was -86.65 percent. As of 02:10 KST on November 11, 2026, the share price was KRW 1,300, down 5.45 percent, with a market capitalization of KRW 3.1 billion. Trading value of KRW 1.014 million reflects very limited liquidity. Under these conditions, small trades can move the price significantly.

07

Risk factors

Macro

Demand in the in-vitro diagnostics market has weakened since the COVID-19 testing peak, and competition has intensified. Smaller firms face difficulty defending share against larger diagnostics companies and new entrants competing on price and technology.

Interest rates and economic conditions can also affect equipment spending and consumable purchases by hospitals and testing labs. These external factors will shape how quickly revenue can recover.

Regulatory

In-vitro diagnostic devices require product-specific approvals and certifications, and commercialization of new products can slip with regulatory timelines. The saliva-based diagnostics are still in development, so clinical performance and approval requirements remain to be confirmed.

A move to a SaaS subscription model would also bring software and personal data rules into play. Delays in regulatory schedules would also delay the effect of the business model shift.

Liquidity and capital structure

Equity of KRW 260 million is thin and liabilities are close to total assets, leaving limited financial room. With operating cash flow negative in 2025, additional funding may be needed. Trading value of KRW 1.014 million on the Konex market suggests constraints on both fundraising and share circulation. Changes in the capital structure and funding terms will be visible in future disclosures.

08

Overall view

Calth is a small Konex-listed company built on in-vitro diagnostic technology. Weak factors include continuing sales declines and operating losses, while supportive factors include equity turning positive and plans to expand into saliva diagnostics and a SaaS subscription model.

Standalone revenue in 2025 was KRW 1.686 billion and the operating loss was KRW 4.0 billion, with equity of KRW 260 million still below the capital stock. The reason for the equity change and the timing of the business shift in reported results will be visible in future filings.

The 12-month share price change was -86.65 percent as of September 3, 2025, and small trading value limits price stability. Although the sector is classified as electrical equipment, the business is diagnostics, which limits direct comparison with listed peers in that sector.

This is a qualitative summary for information purposes and does not offer a view on the direction of the share price.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 7 more articles and sources
  1. m.news.nate.com
  2. saramin.co.kr
  3. jobkorea.co.kr
  4. prestocknews.com
  5. prestocknews.com
  6. comp.fnguide.com
  7. markets.hankyung.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis